The effectiveness of vedolizumab on mucosal inflammation in PSC-IBD was comparable to that observed in non-PSC-IBD cohorts;23 however, lower response rates were reported for anti-TNF alpha inhibitors in PSC-IBD compared to non-PSC-IBD cohorts.24 This evidence concerns the gene TNF and inflammatory bowel disease.